Amgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim rights to an OX40-targeting drug from Kyowa Kirin that is ready for phase 3 testing for atopic ...

Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, ...

Paraganglioma Global Market Report 2025 - Market Size, Trends, And Global Forecast 2025-2034 The Business Research Company's Global Panuvei ...

Fujifilm Kyowa Kirin Biologics granted Mylan an exclusive licence to commercialise its version of adalimumab, Hulio, in Europe. Amgen, Biogen and Samsung Bioepis have all have been granted ...

Story Feb. 4 - Kyowa Kirin: The Japanese pharma is letting go ... shrinking its head count by 40% and reassessing the future of Amgen-partnered T-cell engager CX-904 as a way to save cash and ...

The Japanese pharmaceutical company Kyowa Kirin Co. plans to sell shares in the Chinese division of the Hong Kong company WinHealth Pharma Group Co. for 15 billion yen ($100 million) as part of the ...

Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen AMGN revealed 19 unusual trades. Delving into the details, we found 26% of traders were ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The company’s shares closed yesterday at $314.38.

Beer and records are two perfect examples. In partnership with the legendary DJ and Deus Records, premium Japanese beer brand Kirin Ichiban delivered an experience rooted in first-press purity ...